New gene therapy halts 2 boys’ rare brain disease
WASHINGTON — French scientists mixed gene therapy and bone marrow transplants in two boys to seemingly halt a brain disease that can kill by adolescence.
The surprise ingredient: They disabled the HIV virus so it couldn’t cause AIDS, and then used it to carry in the healthy new gene.
The experiment marks the first time researchers have tried that long-contemplated step in people — and the first effective gene therapy against a severe brain disease, said lead researcher Dr. Patrick Aubourg of the University Paris-Descartes.
Although it’s a small, first-step study, it has “exciting implications” for other blood and immune disorders that had been feared beyond gene therapy’s reach, said Dr. Kenneth Cornetta, president of the American Society of Gene and Cell Therapy.
“This study shows the power of combining gene therapy and cell therapy,” added Cornetta, whose own lab at Indiana University has long researched how to safely develop gene delivery using lentiviruses, HIV’s family.
The research was published in Friday’s edition of the journal Science.
In 20 years of gene therapy research, there have been few home runs and some headline-making setbacks — including a risk of leukemia caused by otherwise successful gene therapy for another rare disorder, “bubble boy disease.” That’s a risk that specialists hope a lentivirus-based gene therapy will eliminate.
Best known from the movie “Lorenzo’s Oil”, adrenoleukodystrophy, or ALD, is a rare genetic disease that, in its most devastating form, destroys the coating of nerve fibers in boys’ brains. Without that coating, called myelin, the neurological system breaks down. The disease typically strikes between the ages of four and 10, leading to blindness, deafness, dementia and loss of muscle control, and killing them within a few years.
Bone marrow transplants can halt ALD by letting new myelin-forming stem cells take root. But it’s difficult to find a matching marrow donor, and the transplant itself is very risky.
So what if stem cells from the boys’ own bone marrow could be genetically corrected, eliminating the ALD mutation? To do that, Aubourg’s team had to overcome a technical hurdle: Gene therapy works when scientists harness deliver a healthy new gene by attaching to a virus that can harmlessly infect cells. But none of today’s so-called gene therapy “vectors” could penetrate enough of the stem cells needed for an ALD treatment to work.
Unlike most viruses, HIV can penetrate stem cells, and it sticks permanently. So Aubourg’s team removed the genetic parts of HIV that make it dangerous, leaving basically a scaffolding to carry the new therapeutic gene.
Then they culled stem cells from two 7-year-old boys in the early stages of ALD, and mixed in the healthy gene. The boys underwent bone marrow-destroying chemotherapy and then had their genetically corrected stem cells reinserted.
Two years later, the boys have shown no sign of worsening brain damage and are functioning well with 15 percent of their blood cells producing the healthy protein, said Aubourg, who plans to test the experimental procedure in more patients. An advocacy group, the Stop ALD Foundation, is working to raise money for a similar U.S. study.
On the Net:
Science Web site: www.sciencemag.org
Related News
Rare brain disorder which causes dementia is geneticNovember 5th, 2009 LONDON - New research shows that a rare brain disorder that causes early dementia is highly hereditary. The brain disorder called frontotemporal dementia destroys parts of the brain, leading to dementia, including problems with language or changes in behaviour and personality.
Scientists using gene therapy to stall Huntington's diseaseOctober 31st, 2009 WASHINGTON - Scientists from California Institute of Technology (Caltech) have suggested a gene therapy that is capable of stalling the development of Huntington's disease. Huntington's disease is a neurodegenerative disorder with a genetic basis.
FDA approves Merck's cervical cancer vaccine Gardasil to prevent genital warts in boysOctober 16th, 2009 FDA approves Merck's Gardasil for boysWASHINGTON — Drugmaker Merck said Friday that U.S. regulators cleared its vaccine Gardasil to prevent genital warts in boys, a new use for a product already approved to prevent cervical cancer in women.
Scientists using gene therapy to treat Parkinson's diseaseOctober 15th, 2009 LONDON - Scientists from French Atomic Energy Commission's Institute of Biomedical Imaging in Orsay are using gene therapy to treat Parkinson's disease. While the research conducted over monkeys has shown, trials over human patients are underway.
Trials to test gene therapy for Parkinson's disease underwayOctober 7th, 2009 WASHINGTON - Scientists at Michigan hospital have launched a trial to test gene transfer therapy that would help restore better mobility in Parkinson's patients who have lost responsiveness to drug therapy. When brain neurons in brain begin to die, the cells can no longer manufacture the molecule dopamine, a chemical critical for controlling movement.
Trials to test efficacy of gene therapy for Alzheimer's underwaySeptember 23rd, 2009 WASHINGTON - Scientists from Georgetown University Medical Center are conducting a trial to check the efficacy of gene therapy as a potential treatment for patients with dementia due to Alzheimer's disease. The trial will test the benefits of CERE-110, which contains a gene that is injected during surgery into a part of the brain affected by Alzheimer's disease.
New method to turn blood-brain barrier into therapy delivery systemSeptember 22nd, 2009 LONDON - Researchers at University of Iowa have discovered a way to turn the blood brain barrier into a production and delivery system for getting therapeutic molecules directly into brain cells. Working with animal models of a group of fatal neurological disorders called lysosomal storage diseases, the researchers found that these diseases cause unique and disease-specific alterations to the blood vessels of the blood brain barrier.
Gene therapy may soon be helping dieters keep off weight gainSeptember 21st, 2009 LONDON - Researchers from Columbia University have suggested a gene therapy that will allow dieters to eat less and burn calories at the same rate as they do when eating normally, thus helping them keep off weight gain. During the study, the team genetically engineered a group of to limit the action of a gene called Cpe.
Central NY resident has rare brain disease spread by mosquitoes; swamp to be sprayedSeptember 11th, 2009 Central NY resident has rare brain virusSYRACUSE, N.Y. — Health officials say a central New York resident has been diagnosed with Eastern Equine Encephalitis, a rare and potentially fatal brain infection spread by mosquitoes.
New Alzheimer's-related genes identifiedSeptember 7th, 2009 LONDON - A group of British scientists have identified two new genes that are linked with Alzheimer's disease. After analysing the gene pool of more than 19,000 older European and U.S.
Largest Alzheimer's study unravels its mysteriesSeptember 7th, 2009 LONDON - The largest study so far on Alzheimer's disease has helped British and French scientists isolate three new genes associated with it. They are the first new genes found to be associated with the common form of Alzheimer's disease since 1993.
Missing protein in rare genetic brain disorder restoredSeptember 7th, 2009 WASHINGTON - By using protease inhibitors, researchers at the University of California-San Francisco (UCSF) have restored to normal levels a key protein that is involved in early brain development, and causes the rare brain disorder lissencephaly. Reduced levels of the protein called LIS1 have been shown to cause lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants.
Scientists imitate viruses to deliver therapeutic genesSeptember 1st, 2009 WASHINGTON - Australian scientists have developed a new gene therapy vector that uses the same machinery as viruses to transport their cargo into cells. David Jans, from the Nuclear Signaling Laboratory at Monash University in Victoria, says that this achievement has raised the hope that one day therapeutic DNA will begin to be transferred to a cell's nucleus far more efficiently than in the past, and thus there will be more effective treatments for several genetic disorders and some types of cancers.
Novel therapeutic target for Parkinson's disease identifiedAugust 29th, 2009 WASHINGTON - Scientists from University of Helsinki Institute of Biotechnology have identified a novel therapeutic target for Parkinson's disease. Lead researcher Professor Raimo K.
Common drug can function as 'off switch' for Parkinson therapyAugust 29th, 2009 WASHINGTON - A common antibiotic can act as an "off switch" for a gene therapy that is being developed for Parkinson's disease, according to a study on rats conducted by University of Florida researchers. The findings of the study have explained how new, therapeutic genes that have been irrevocably delivered to the human brain to treat Parkinson's can be controlled if the genes unexpectedly start causing problems.
